ReviewAnnals of translational medicine2018
Ventilator-associated pneumonia in extracorporeal membrane oxygenation-assisted patients.
Review in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Extracorporeal Membrane Oxygenation Use in Fat Embolism Syndrome: Current Perspectives and Clinical Insights (A 20-Year Review).Journal of clinical medicine · 2025Review
- Lung injury in myocardial infarction-associated cardiogenic shock supported by venoarterial extracorporeal membrane oxygenation: a scoping review.BMC cardiovascular disorders · 2025Article
- Clinical Characteristics of Fever After Extracorporeal Membrane Oxygenation Decannulation: Differentiating Infectious from Non-Infectious Causes of Fever and Their Impact on Outcomes.Journal of clinical medicine · 2024Article
- Multidrug-resistant pathogens and ventilator-associated pneumonia in critically ill COVID-19 and non-COVID-19 patients: a prospective observational monocentric comparative study.Respiratory research · 2024Article
- Fever and Leukocytosis Are Poor Predictors of Bacterial Coinfection in Patients With COVID-19 and Influenza Who Are Receiving Extracorporeal Membrane Oxygenation.Open forum infectious diseases · 2023Article
- Ventilator-Associated Pneumonia in COVID-19 Patients Admitted in Intensive Care Units: Relapse, Therapeutic Failure and Attributable Mortality-A Multicentric Observational Study from the OutcomeRea Network.Journal of clinical medicine · 2023Article
- Timing of tracheostomy and patient outcomes in critically ill patients requiring extracorporeal membrane oxygenation: a single-center retrospective observational study.Journal of intensive care · 2022Article
- Empiric Treatment in HAP/VAP: "Don't You Want to Take a Leap of Faith?"Antibiotics (Basel, Switzerland) · 2022Review
- Delayed Initiation of ECMO Is Associated With Poor Outcomes in Patients With Severe COVID-19: A Multicenter Retrospective Cohort Study.Frontiers in medicine · 2021Article
- Risk factors and prognosis of nosocomial pneumonia in patients undergoing extracorporeal membrane oxygenation: a retrospective study.The Journal of international medical research · 2020Article
- Pulmonary complications associated with veno-arterial extra-corporeal membrane oxygenation: a comprehensive review.Critical care (London, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracorporeal membrane oxygenation (ECMO) provides a circulatory and/or respiratory assistance in case of refractory cardiogenic shock or acute respiratory distress syndrome (ARDS). Due to their extreme critical illness, these patients usually require prolonged mechanical ventilation, which is an inherent risk of ventilator-associated pneumonia (VAP). Although microorganisms responsible of VAP on ECMO are similar to those found in non-ECMO patients, classical suspicion criteria of VAP are no longer relevant on ECMO. Frequent severe chest X-Ray impairments, and poor specificity of the classical biomarkers on ECMO make VAP diagnosis challenging. In addition, significant drug pharmacokinetic modifications by the device may lead to low plasmatic antibiotic concentration and potential treatment failure. Consequently, rate of treatment failure and relapse appear high in that population (up to 30%), with significant impact on mortality and on the ECMO duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.